The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group

The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group

The study hypothesis is that erythropoietin usage after kidney transplantation, in early phase, can improve the outcome for patients and their graft increasing patient and graft survival.

Inclusion Criteria:

• Hb: >8 and <10 gr/dl
• Age: >18 and <55 years
• Cholesterol: <300 mg/dl
• Triglyceride: <400 mg/dl
• First Transplantation
• Protocol of Immunosuppression: CSA + MMF + Prednisolone
• Systolic BP: <14
• Diastolic BP: <9

Exclusion Criteria:

• History of specified cardiac disease
• Second Transplantation or more
• Hb: <7gr/dl
• The patient needs to infusion of blood
• Evidence of local or systemic infection, at the time of EPO injection
• Presence of ATN / DGF after transplantation
• Presence of emergent hypertension
• High risk patients ( Like; PRA>50%)
• Past history of hypersensitivity